Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 10 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Acalabrutinib with venetoclax and obinutuzumab for treating previously untreated chronic lymphocytic leukaemia	Acalabrutinib (Calquence; ACP-196) , Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Chronic lymphocytic leukaemia (CLL)	Haematological Cancer and Lymphomas	2022	View \| Download
Acalabrutinib with venetoclax for previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma	Acalabrutinib (Calquence; ACP-196) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL)	Haematological Cancer and Lymphomas	2022	View \| Download
Ibrutinib in combination with venetoclax for chronic lymphocytic leukaemia or small lymphocytic lymphoma – first line	Ibrutinib (Imbruvica) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL)	Haematological Cancer and Lymphomas	2020	View \| Download
Ibrutinib with Venetoclax and Obinutuzumab for the treatment of Chronic Lymphocytic Leukaemia patients with TP53 deletion and/or mutation	Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Chronic lymphocytic leukaemia (CLL)	Haematological Cancer and Lymphomas	2017	View \| Download
Venetoclax in addition to ibrutinib for relapsed mantle cell lymphoma – second-line and beyond	Ibrutinib (Imbruvica) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Mantle cell lymphoma	Haematological Cancer and Lymphomas	2020	View \| Download
Venetoclax in combination with a hypomethylating agent or low dose cytarabine for newly diagnosed acute myeloid leukaemia	hypomethylating agent , Low-dose cytarabine , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2018	View \| Download
Venetoclax in combination with azacitidine for myelodysplastic syndrome	Azacitidine (Vidaza; CC-486) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Myelodysplastic syndrome (MDS)	Haematological Cancer and Lymphomas	2023	View \| Download
Venetoclax in combination with bortezomib and dexamethasone for relapsed multiple myeloma - second line and beyond	Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2018	View \| Download
Venetoclax in Combination with Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukaemia – First Line	Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Chronic lymphocytic leukaemia (CLL)	Haematological Cancer and Lymphomas	2017	View \| Download
Venetoclax with dexamethasone for previously treated relapsed/refractory multiple myeloma	Dexamethasone (dexamethasone sodium metasulfobenzoate) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2021	View \| Download

About

Devices, Diagnostics & Digital

About

Data Science & AI

Devices, Diagnostics & Digital

Insights (Public/Patient)

Medicines

Medicine Industry's Gateway to NICE

Support for Industry

Outputs & Publications